Skip to content
Screener

Aclaris Therapeutics ACRS Drug Discovery Platform — Research And Development Project Spend

Similar metrics at other companies

Axe Compute Inc. logo
AGPUDrug Discovery Services — Research And Development Expense
$2.14M+283%
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%
ArriVent BioPharma, Inc. logo
AVBPDrug Firmonertinib — Research And Development Expense
$15.08M+5.4%
Tyra Biosciences, Inc. logo
TYRAFGFR Discovery — Research And Development Expense
$2.53M-19.2%
Kura Oncology logo
KURADiscovery Stage Program — Research And Development Expense
$1.4M-33.0%
Zymeworks logo
ZYMEOther drug supply — Research and development collaborations
$1.66M+23,671%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.56M+389%
Enterprise value$851.24M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.

The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092065
(In thousands)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
ATI-0524,8991,4188,0802,037
Modzatinib3701,1188612,926
ATI-94943,0568715,2811,549
Discovery1,9727493,4111,417
Total research and development project expense(1)13,6327,00324,10914,160
Personnel3,0362,9846,3175,911
Other research and development(2)1,3981,4623,2972,962
Total research and development18,06611,44933,72323,033

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's drug discovery platform — research and development project spend?
Aclaris Therapeutics (ACRS) reported drug discovery platform — research and development project spend of $1.97M in Q2 2026.
How has Aclaris Therapeutics's drug discovery platform — research and development project spend changed year-over-year?
Aclaris Therapeutics's drug discovery platform — research and development project spend increased by 163.3% year-over-year, from $749K to $1.97M.
What does drug discovery platform — research and development project spend mean?
This metric represents the total capital and operational expenditure allocated specifically to research and development activities within the drug discovery platform segment. It reflects the company's investment intensity in advancing its pipeline of novel therapeutic candidates and early-stage scientific innovation. Monitoring this spend helps investors assess the company's commitment to long-term growth and the pace of its internal drug development efforts.

Ask your AI about Aclaris Therapeutics's drug discovery platform — research and development project spend.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude